Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of Postal Ballot Notice18-05-2024
18-05-2024
Mankind Pharma Ltd - 543904 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice17-05-2024
Mankind Pharma Q4 Results Review - Strong Performance From Formulation; Consumer Health Subdued: Dolat Capital
Export business shows exponential growth on low base and one-offs17-05-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Conference Call for Q4FY24 - Audio Recording16-05-2024
Mankind Pharma looking at acquisitions, keeping funds ready for an opportunity, says management
The company has an enabling or blanket approval to be ready for a big or small acquisition16-05-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of consolidated audited financial results for the quarter and financial year ended on March 31, 2024.16-05-2024
Mankind Pharma Results Earnings Call for Q4FY24
Conference Call with Mankind Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.16-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Mankind Pharma Ltd.
Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations at Rs 2,441 crore, up by 19% YoY Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY EBITDA margin of 24.3%, and PAT margin of 19.5% Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1) FY24 Financial Highlights: Revenue from Operations at Rs 10,335 crore, up by 18% Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175% EBITDA margin of 24.7%, and PAT margin of 18.8% Diluted EPS of Rs 47.7, up by 49% (FV Re.1) Cash flow from operations of Rs 2,152 crore, up by 19% Net cash balance of Rs 3,260 crore as on 31st March 2024 Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23. Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%. We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca. Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.” Result PDF16-05-2024
Mankind Pharma Ltd - 543904 - Clarification On News Item Appearing In Www.Business-Standard.Com
Clarification on news item appearing in www.business-standard.com15-05-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and financial year ended 31st March 2024.15-05-2024